Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Reports outline vaccines study results from Cancer Research UK London Research Institute
March 25th, 2009
New investigation results, 'Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines,' are detailed in a study published in Gene Therapy. "Replicon plasmids encoding an alphavirus RNA replicase constitute an alternative to conventional DNA plasmids with promise for DNA vaccination in humans. Replicase activity amplifies the levels of transgene mRNA through a copying process involving double-stranded (ds) RNA intermediates, which contribute to vaccine immunogenicity by activating innate antiviral responses," scientists in London, the United Kingdom report. "Toll-like receptor 3 (TLR3) is a dsRNA innate immune receptor expressed by antigen-presenting...
Source: Vaccine Weekly (2009-03-25)
|
